Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 7/20 | 0.38 |
| ▸ | KIF11 | P52732 | 6/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31073617 | 0.86 | PTPN1 (0.38) | PTPN1BACE1KIF11CTSDREN | |
| SCHEMBL30529860 | 0.85 | PPARG (0.41) | REN | |
| SCHEMBL30163216 | 0.85 | KIF11 (0.41) | KIF11DNMT1 | |
| SCHEMBL31043231 | 0.84 | REN (0.38) | PTPN1BACE1REN | |
| SCHEMBL29374163 | 0.84 | PPARA (0.42) | REN | |
| SCHEMBL30529853 | 0.83 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL30529852 | 0.83 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL30815070 | 0.82 | ACE (0.36) | KIF11REN | |
| SCHEMBL30814959 | 0.82 | ACE (0.36) | KIF11REN | |
| SCHEMBL29755434 | 0.81 | OPRD1 (0.40) | PTPN1BACE1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | PEPTISTAR INC. (JP) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | HDGF, VIP, NPPA | PTPN1 4090/4885BACE1 3899/4885KIF11 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.